MNKD vs NVO
MNKD: MannKind is a biopharmaceutical company specializing in drug-device combinations, including inhaled therapies and on-body infusors, to treat cardiometabolic and orphan lung diseases. NVO: A leading global healthcare company with a heritage in diabetes, pioneering scientific breakthroughs to defeat serious chronic diseases through innovative medicines and expanded access.
Side-by-side fundamentals
| Metric | MNKD | NVO | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.84 | $48.19 | |
| Market cap as of 2026-07-23 | $1.2B | $219.8B | |
| P/E as of 2026-07-23 | 212.36 | 11.78 | NVO lower |
| PEG as of 2026-07-23 | n/a | 16.16 | |
| Net margin as of 2026-07-23 | -6.4% | +37.2% | NVO higher |
| Gross margin as of 2026-07-23 | +78.4% | +81.8% | NVO higher |
| Operating margin as of 2026-07-23 | +4.1% | +45.3% | NVO higher |
| ROE as of 2026-07-23 | -297.7% | +66.4% | NVO higher |
| ROA as of 2026-07-23 | -3.8% | +23.3% | NVO higher |
| Debt / equity as of 2026-07-23 | 9.95 | 0.72 | NVO lower |
| Revenue growth (YoY) as of 2026-07-23 | +21.2% | +8.1% | MNKD higher |
| Revenue CAGR (3y) SEC XBRL | +51.8% | n/a | |
| Dividend yield as of 2026-07-23 | n/a | +3.7% | |
| Beta as of 2026-07-23 | 1.12 | 1.85 | |
| 1-year return as of 2026-07-22 close | -2.3% | -23.8% | MNKD higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.